Transition to once-weekly growth hormone in paediatric isolated growth hormone deficiency: A real-world experience

Clicks: 33
ID: 329677
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #46 of 122 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: To evaluate real-world auxological and biochemical outcomes in children and adolescents with isolated growth hormone deficiency (GHD) who transitioned from daily recombinant human growth hormone to once-weekly somatrogon. DESIGN: Single-centre retrospective observational study. METHODS: Seventy-three paediatric patients with isolated GHD (52 boys) transitioned to weekly somatrogon at a mean age of 12.56 ± 2.87 years. At the time of data collection, all 73 patients had completed 6 months of follow-up, while 58 and 27 patients had completed 12 and 18 months, respectively. Primary outcomes were changes in height standard deviation score (SDS) and height velocity SDS. Secondary outcomes included body mass index (BMI) SDS, weight SDS, and serum insulin-like growth factor-1 (IGF-1) SDS. Assessments were performed 6 months prior to transition and at 6, 12, and 18 months after initiation of long-acting growth hormone therapy. RESULTS: Height SDS increased, while height velocity SDS remained positive throughout follow-up. BMI SDS increased significantly during the first year after transition but stabilized by 18 months. Serum IGF-1 SDS showed an early increase at 6 months and subsequently declined. CONCLUSIONS: Transition from daily growth hormone to once-weekly somatrogon maintained effective growth outcomes in paediatric patients with isolated GHD. These findings support the effectiveness of weekly therapy in routine clinical practice. Further long-term studies are needed to better characterize metabolic effects and inform individualized treatment strategies.
Reference Key
openalex_W7214218838 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Georgia Sotiriou, Maria Moutafi, Panagiota Triantafyllou, Maria Papagianni, Athanasios Christoforidis
Are you one of these authors? Claim your profile
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag185
URL
https://doi.org/10.1093/ejendo/lvag185
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.